Mylotarg: Antibody-targeted chemotherapy comes of age

Current Opinion in Oncology

Volumn 13, Issue 6, 2001, Pages 522-527

  Sievers, Eric L ^a,b   Linenberger, Michael ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CD33 ANTIGEN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER TOXICITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW;

AGED; ALANINE TRANSAMINASE; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; CLINICAL TRIALS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; NEUTROPENIA; PATIENT SELECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034753903     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200111000-00016     Document Type: Review

References (29)

1. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia: Southwest Oncology Group Study
2. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia
3. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
4. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
5. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia
6. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): Preliminary report of a phase II study
7. Engagement of CD33 surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid precursors
8. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells
9. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
10. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed
11. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model
12. Calicheamicin gamma 11: An antitumor antibiotic that cleaves double-stranded DNA site specifically
13. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
14. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
15. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
16. Interaction of calicheamicin gamma1 (I) and its related carbohydrates with DNA-protein complexes
17. DNA-cleaving properties of calicheamicin gamma1 (I)
18. Cell-specific regulation of apoptosis by designed enediynes
19. Multidrug resistance phenotype and clinical responses to gemtuzumab ozogamicin
20. The origins of DNA breaks: A consequence of DNA damage, DNA repair, or apoptosis?
21. Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg, CMA-676) in pediatric patients with acute myeloid leukemia
22. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse
23. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study
24. Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg, CMA-676) followed by hematopoietic stem cell transplantation
25. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in the treatment of patients with acute myeloid leukemia in first relapse
26. Low incidence of hepatic venoocclusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): Relation to hematopoietic stem cell transplantation
27. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
28. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
29. Biological activities of calicheamicin